2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide | 920868-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide
• 英文别名: 2-[2-[(5-cyclopropyl-4-phenyl-1,2,4-triazol-3-yl)sulfanyl]propanoylamino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide
• CAS: 920868-45-7
• 化学式: C₂₂H₂₃N₅O₂S₂
• 分子量: 453.589
• InChiKey: MTAWXPCGCQTSOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  156
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(cyclopropylcarbonyl)-N-phenylhydrazinecarbothioamide 在 potassium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 生成 2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide
  参考文献：
  名称：

  [EN] MITOFUSIN INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE LA MITOFUSINE ET LEURS UTILISATIONS

  摘要：

  Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activation and DNA damage signaling. Also disclosed are methods of treating diseases or conditions associated with imbalanced mitochondrial dynamics.

  公开号：

  WO2023107880A1

文献信息

• Small molecule regulators of mitochondrial fusion and methods of use thereof
  申请人：Washington University

  公开号：US10844023B2

  公开（公告）日：2020-11-24

  Compositions comprising small molecule mitofusin agonists are described. The mitofusin modulating agents are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that regulate mitochondrial function are also described.

  本文描述了包含小分子丝裂霉素激动剂的组合物。丝裂素素调节剂可用于治疗与线粒体相关的疾病、紊乱或病症，如与丝裂素素1（Mfn1）和/或丝裂素素2（Mfn2）或线粒体功能障碍相关的疾病或紊乱。还描述了治疗方法、药物制剂和用于鉴定调节线粒体功能的化合物的筛选方法。
• Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
  申请人：MITOCHONDRIA EMOTION, INC.

  公开号：US11083699B2

  公开（公告）日：2021-08-10

  Compounds and compositions including stereoisomers of 6-phenylhexanamide derivative small molecule mitofusin activators are described. In particular, mitofusin activators comprising derivatives of (trans-4-hydroxycyclohexyl)-6-phenylhexanamide, which are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin-1 (MFN1) and/or mitofusin-2 (MFN2), or mitochondrial dysfunction, are described. Methods of treatment and pharmaceutical formulations are also described.

  描述了包括 6-苯基己酰胺衍生物小分子丝裂霉素激活剂立体异构体的化合物和组合物。特别是，描述了包括(反式-4-羟基环己基)-6-苯基己酰胺衍生物的丝裂霉素激活剂，该激活剂可用于治疗与线粒体相关的疾病或失调，如与丝裂霉素-1 (MFN1)和/或丝裂霉素-2 (MFN2)或线粒体功能障碍相关的疾病或失调。还描述了治疗方法和药物制剂。
• Mitofusin activators and methods of use thereof
  申请人：MITOCHONDRIA EMOTION, INC.

  公开号：US11026904B2

  公开（公告）日：2021-06-08

  Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.

  本文描述了包括小分子丝裂霉素激活剂的组合物。丝裂磷蛋白激活剂可用于治疗与线粒体相关的疾病或失调，如与丝裂磷蛋白1（MFN1）和/或丝裂磷蛋白2（MFN2）或线粒体功能障碍相关的疾病或失调。此外，还介绍了治疗方法、药物制剂以及用于鉴定激活线粒体融合的化合物的筛选方法。
• SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF
  申请人：Wahington University

  公开号：US20190169138A1

  公开（公告）日：2019-06-06

  Compositions comprising small molecule mitofusin agonists are described. The mitofusin modulating agents are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that regulate mitochondrial function are also described.
• MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF
  申请人：MITOCHONDRIA EMOTION, INC.

  公开号：US20200345669A1

  公开（公告）日：2020-11-05

  Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.